| 1 |
34196811 | Lipoprotein(a). | 2022 |
1 |
| 2 |
34375677 | Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China. | 2022 Apr |
1 |
| 3 |
34582002 | Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. | 2022 Mar |
1 |
| 4 |
34758978 | Effect of Loss-of-Function Genetic Variants in PCSK9 on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function. | 2022 Jan 1 |
1 |
| 5 |
34809446 | PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular Disease. | 2022 Jan |
5 |
| 6 |
34907967 | Therapeutic application of genome editing in dyslipidemia. | 2022 Apr 1 |
1 |
| 7 |
34922870 | Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab. | 2022 Apr |
1 |
| 8 |
35007650 | Associations of pro-protein convertase subtilisin-like kexin type 9, soluble low-density lipoprotein receptor and coronary artery disease: A case-control study. | 2022 Mar 1 |
2 |
| 9 |
35048716 | Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. | 2022 Feb |
2 |
| 10 |
35050192 | Gene Therapy Targeting PCSK9. | 2022 Jan 12 |
1 |
| 11 |
35052871 | Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study. | 2022 Jan 17 |
1 |
| 12 |
35159928 | The Impact of the COVID-19 Outbreak on Patients' Adherence to PCSK9 Inhibitors Therapy. | 2022 Jan 18 |
1 |
| 13 |
35162992 | Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. | 2022 Jan 19 |
9 |
| 14 |
35175350 | Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. | 2022 Jun 6 |
1 |
| 15 |
35213538 | Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. | 2022 Feb |
1 |
| 16 |
35221836 | Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management. | 2022 |
2 |
| 17 |
35237909 | Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells. | 2022 Jun |
2 |
| 18 |
35246337 | Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes. | 2022 Feb |
1 |
| 19 |
35252378 | Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review. | 2022 |
2 |
| 20 |
35263196 | The Biological Relevance of PCSK9: When Less Is Better…. | 2022 Mar 9 |
4 |
| 21 |
35294778 | Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments? | 2022 Jul |
1 |
| 22 |
35307759 | Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. | 2022 Jun |
1 |
| 23 |
35320320 | Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia). | 2022 |
4 |
| 24 |
35323658 | The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases. | 2022 Feb 26 |
1 |
| 25 |
35326219 | Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis. | 2022 Mar 16 |
2 |
| 26 |
35336039 | Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity. | 2022 Mar 18 |
2 |
| 27 |
35381104 | Latest clinical evidence about the effect of PCSK9 monoclonal antibodies in patients with familial hypercholesterolaemia: an updated meta-analysis. | 2022 |
2 |
| 28 |
35387881 | PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function. | 2022 Jun |
1 |
| 29 |
35454343 | Ramadan Intermittent Fasting Is Associated with Changes in Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Metabolically Healthy Obese Subjects. | 2022 Mar 31 |
2 |
| 30 |
35467263 | Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9. | 2022 Apr 25 |
1 |
| 31 |
35494422 | The Relationship of Circulating Proprotein Convertase Subtilisin/Kexin Type 9 With TSH and Lipid Profile in Newly Diagnosed Patients With Subclinical and Overt Hypothyroidism. | 2022 |
1 |
| 32 |
35508320 | PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. | 2022 May 4 |
1 |
| 33 |
35552680 | The Multifaceted Biology of PCSK9. | 2022 May 12 |
1 |
| 34 |
35571202 | Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism. | 2022 |
2 |
| 35 |
35585420 | Retinoic acid increases the cellular cholesterol predominantly in a mTOR-independent manner. | 2022 May 18 |
2 |
| 36 |
35599686 | Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways. | 2022 |
1 |
| 37 |
35600486 | Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease. | 2022 |
2 |
| 38 |
32090592 | Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9? | 2021 |
3 |
| 39 |
32875580 | Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall. | 2021 Apr |
1 |
| 40 |
32988222 | PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. | 2021 Jan 5 |
1 |
| 41 |
32991689 | PCSK9 and LRP5 in macrophage lipid internalization and inflammation. | 2021 Jul 27 |
2 |
| 42 |
33091218 | PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. | 2021 Feb |
2 |
| 43 |
33108009 | Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia. | 2021 Apr |
3 |
| 44 |
33128247 | Micro- and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipients-An exploratory study. | 2021 Jan |
3 |
| 45 |
33177004 | In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake. | 2021 Mar |
2 |
| 46 |
33226544 | Assessment of Low LDL Cholesterol in Patients Treated by PCSK9 Inhibition: Comparison of Martin/Hopkins and Friedewald Estimations. | 2021 Aug |
1 |
| 47 |
33236356 | PCSK9 and atherosclerosis: Looking beyond LDL regulation. | 2021 Apr |
3 |
| 48 |
33295631 | Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. | 2021 May 14 |
2 |
| 49 |
33307067 | PCSK9: Associated with cardiac diseases and their risk factors? | 2021 Jun 15 |
2 |
| 50 |
33326580 | High-sugar feeding and increasing cholesterol levels in infants. | 2021 Mar 21 |
1 |